A Randomized, Double-blind, Placebo- and Comparator-controlled Study Evaluating the Effect of Multiple Doses of QGE031 Compared to Omalizumab in Asthma Induced by Allergen Bronchial Provocation

Trial Profile

A Randomized, Double-blind, Placebo- and Comparator-controlled Study Evaluating the Effect of Multiple Doses of QGE031 Compared to Omalizumab in Asthma Induced by Allergen Bronchial Provocation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2016

At a glance

  • Drugs Ligelizumab (Primary) ; Omalizumab
  • Indications Allergic asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Jan 2014 As per the Clinicaltrials.gov record, status changed from active, no longer recruiting to completed.
    • 04 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Feb 2013 New source identified and integrated (EudraCT2012-003350-84: European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top